Enforcement & Kickback Risk · Legal Frameworks
One Kickback Now Triggers Three Separate Penalties Under Federal Law
A single kickback fact pattern can now run through three separate legal theories at once. Here's how they connect, and why the split is becoming the standard shape of these resolutions.
In August 2026, a pharmaceutical manufacturer resolved a kickback case for more than $46 million, split across three distinct penalties: a criminal fine, a civil settlement, and a separate civil penalty for inaccurate reporting, according to the Department of Justice's (DOJ) Office of Public Affairs. If you own compliance, legal, or transparency reporting at a life sciences company, that three-way split is the part worth understanding, because it's becoming the standard shape of these resolutions.
The three frameworks, in plain terms
A single kickback fact pattern can now run through three separate legal theories at once:
Track 1 · Criminal
Anti-Kickback Statute (AKS)
Criminalizes offering, paying, soliciting, or receiving remuneration to induce referrals or purchases reimbursed by federal health care programs.
Track 2 · Civil
False Claims Act (FCA)
Imposes civil liability for claims submitted under false pretenses. An AKS-tainted claim is automatically "false" for FCA purposes.
Track 3 · Transparency
CMS Open Payments (Sunshine Act)
A disclosure obligation, not a kickback statute. Inaccurate reporting under it can be penalized on its own, independent of the other two tracks.
That AKS-to-FCA link is what allows one kickback to generate both a criminal conspiracy count and a civil settlement. It's also what allows a private whistleblower to bring a qui tam action on the government's behalf, since the FCA's whistleblower provisions apply once a claim is "false."
The Sunshine Act runs on a separate track. In the August 2026 case, the manufacturer's $1.55 million Open Payments penalty was reportedly the largest since the reporting regime took effect in 2010, according to analysis from Goodwin Procter. The government treated underreporting as an independently penalized violation, not merely supporting evidence for the kickback case.
Why this matters if you own Open Payments reporting
If your job touches transparency, disclosure, or financial reporting rather than the HCP engagement side of compliance, this case is a signal worth taking seriously. Historically, Open Payments accuracy has been treated as a disclosure exercise, something you get right so the company looks compliant. This settlement shows the government willing to penalize a reporting failure on its own terms, independent of whatever kickback case is or isn't proven.
The practical implication: reconciling what HCPs were actually paid against what was reported to CMS isn't just a data hygiene task. It's a standalone compliance control with its own exposure if it fails.
Why this matters if you own HCP engagement or speaker programs
For the compliance and legal side, the takeaway is different but related. An aggressive marketing practice that's fully and accurately disclosed is a different legal position than the same practice paired with underreporting. This case shows the government pursuing both failures at once, and pricing them separately.
The reconciliation point: treat Open Payments reconciliation as part of your kickback risk assessment, not a downstream reporting task owned entirely by someone else.
Frequently asked questions
Can a company be penalized for inaccurate Open Payments reporting even without a kickback finding?
Yes. The Centers for Medicare & Medicaid Services’ (CMS) Open Payments program is a standalone transparency requirement, and inaccurate or incomplete reporting under it can be penalized independently of any Anti-Kickback Statute or False Claims Act liability.
What is a qui tam action?
A qui tam action is a lawsuit filed under the False Claims Act's whistleblower provisions, allowing a private individual, called a relator, to bring a claim on the government's behalf and potentially share in any recovery.
Who enforces the Sunshine Act?
The Centers for Medicare & Medicaid Services (CMS) administers the Open Payments program, commonly known as the Sunshine Act, which requires manufacturers to publicly report payments and transfers of value made to healthcare providers.
Does the FDA get involved in kickback cases?
Not typically. Anti-Kickback Statute and False Claims Act cases are remuneration and reporting-integrity matters, separate from the Food and Drug Administration's (FDA) jurisdiction over product safety and off-label promotion, so the FDA often doesn't appear as an investigating agency in these settlements.
